Plan B Rx-to-OTC switch
This article was originally published in The Tan Sheet
Nonprescription Drugs and Reproductive Health Drugs advisory committees will convene Dec. 16 to "consider the safety and efficacy of NDA 21-045, proposing OTC use of Plan B...for reducing the chance of pregnancy after unprotected sex if contraceptive failed, or birth control was not used." Meeting will begin at 8 A.M. at the Hilton, 620 Perry Parkway, Gaithersburg, Md. Women's Capital Corporation filed the switch application for the emergency contraceptive in April 2003. Barr Labs announced signing a letter of intent to purchase Plan B from WCC Oct. 2. Barr expects a definitive agreement to be reached by mid-November and says the acquisition will not affect efforts to switch the drug OTC (1"The Tan Sheet" Oct. 6, 2003, p. 3)...
You may also be interested in...
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
Increasing clinical trial complexity goes hand in hand with increased reliance on advanced-analysis software. Raj Indupuri of eClinical Solutions believes the company's product will lead this emerging market.
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.